ATE513214T1 - Gelzusammensetzungen - Google Patents

Gelzusammensetzungen

Info

Publication number
ATE513214T1
ATE513214T1 AT02745605T AT02745605T ATE513214T1 AT E513214 T1 ATE513214 T1 AT E513214T1 AT 02745605 T AT02745605 T AT 02745605T AT 02745605 T AT02745605 T AT 02745605T AT E513214 T1 ATE513214 T1 AT E513214T1
Authority
AT
Austria
Prior art keywords
gel
analyte
moieties
sol
entities
Prior art date
Application number
AT02745605T
Other languages
English (en)
Inventor
Margaret Joan Taylor
Original Assignee
Univ Montfort
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Montfort filed Critical Univ Montfort
Application granted granted Critical
Publication of ATE513214T1 publication Critical patent/ATE513214T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G01N33/559—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody through a gel, e.g. Ouchterlony technique
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
    • G01N33/548—Carbohydrates, e.g. dextran
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Colloid Chemistry (AREA)
AT02745605T 2001-07-10 2002-07-10 Gelzusammensetzungen ATE513214T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0116860.8A GB0116860D0 (en) 2001-07-10 2001-07-10 Gel compositions
PCT/GB2002/003183 WO2003006993A2 (en) 2001-07-10 2002-07-10 Gel compositions

Publications (1)

Publication Number Publication Date
ATE513214T1 true ATE513214T1 (de) 2011-07-15

Family

ID=9918254

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02745605T ATE513214T1 (de) 2001-07-10 2002-07-10 Gelzusammensetzungen

Country Status (9)

Country Link
US (1) US8247391B2 (de)
EP (1) EP1407267B1 (de)
JP (2) JP2004534103A (de)
AT (1) ATE513214T1 (de)
DK (1) DK1407267T3 (de)
ES (1) ES2368036T3 (de)
GB (1) GB0116860D0 (de)
PT (1) PT1407267E (de)
WO (1) WO2003006993A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0116860D0 (en) 2001-07-10 2001-09-05 Univ Montfort Gel compositions
DE10254636A1 (de) * 2002-11-22 2004-06-09 Capsulution Nanoscience Ag Verfahren zum Modifizieren von Mikropartikeln sowie Vorrichtung zum Modifizieren von Mikropartikeln
AU2005294200A1 (en) * 2004-10-08 2006-04-20 Georgia Tech Research Corporation Microencapsulation of cells in hydrogels using electrostatic potentials
KR20110106440A (ko) * 2009-01-14 2011-09-28 코넬 유니버시티 생체의료 용도를 위한 생분해성 히드로겔의 제법
CN101745114B (zh) * 2009-12-25 2013-01-23 浙江工业大学 一种对葡萄糖敏感可自控释胰岛素的生物材料的制备方法
US20140350370A1 (en) * 2013-04-08 2014-11-27 The Texas A&M University System Glucose sensing assay
GB201310185D0 (en) 2013-06-07 2013-07-24 Univ Montfort Container
GB201314640D0 (en) * 2013-08-15 2013-10-02 Univ Montfort Matrix gel
RU2719584C2 (ru) 2015-04-21 2020-04-21 Норт Каролина Стейт Юниверсити Глюкозочувствительная система доставки инсулина с использованием чувствительных к гипоксии нанокомпозитов
US11141486B2 (en) * 2015-10-23 2021-10-12 National University Corporation Tokyo Medical And Dental University Drug delivery device
WO2018085809A1 (en) 2016-11-07 2018-05-11 North Carolina State University Patch loaded with dual-sensitive vesicles for enhanced glucose-responsive insulin delivery
NO343313B1 (en) * 2017-03-15 2019-01-28 Lifecare As Fluid composition, method for preparing the composition and use
CN113614840A (zh) * 2018-12-18 2021-11-05 强生消费者公司 个性化局部施用贴剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4705503A (en) * 1986-02-03 1987-11-10 Regents Of The University Of Minnesota Metabolite sensor including a chemical concentration sensitive flow controller for a drug delivery system
GB9200638D0 (en) * 1992-01-10 1992-03-11 Leicester Polytechnic Drug system
DE4203466A1 (de) 1992-02-04 1993-08-05 Rudolf Prof Dr Ehwald Affinitaets-sensor
GB9313484D0 (en) * 1993-06-30 1993-08-11 Univ Montfort Drug system ii
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
JP3536186B2 (ja) * 1995-02-27 2004-06-07 独立行政法人 科学技術振興機構 生体内分解性高分子ヒドロゲル
US5889028A (en) * 1996-02-09 1999-03-30 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
WO1998022097A2 (en) * 1996-11-20 1998-05-28 Bio Advances, Llc Controlled release matrix composition using polar polymer or monomer and poly(acrylic acid) blend
GB9805896D0 (en) 1998-03-20 1998-05-13 Eglise David Remote analysis system
ATE280588T1 (de) * 1998-08-10 2004-11-15 Amgen Inc Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
KR100771711B1 (ko) * 1999-08-27 2007-10-30 엠-바이오테크, 인코포레이티드 글루코스 바이오센서
GB0116860D0 (en) 2001-07-10 2001-09-05 Univ Montfort Gel compositions

Also Published As

Publication number Publication date
EP1407267B1 (de) 2011-06-15
DK1407267T3 (da) 2011-09-19
JP2004534103A (ja) 2004-11-11
ES2368036T3 (es) 2011-11-11
US20040265386A1 (en) 2004-12-30
JP2011144197A (ja) 2011-07-28
EP1407267A2 (de) 2004-04-14
JP5405511B2 (ja) 2014-02-05
WO2003006993A2 (en) 2003-01-23
PT1407267E (pt) 2011-09-19
WO2003006993A3 (en) 2003-09-25
GB0116860D0 (en) 2001-09-05
US8247391B2 (en) 2012-08-21

Similar Documents

Publication Publication Date Title
ATE513214T1 (de) Gelzusammensetzungen
FR14C0064I2 (fr) Anticorps anti-il-6, compositions, methodes et utilisations associees
TR200102029T2 (tr) 1-Heterosiklil ikameli diarilaminler.
ATE465748T1 (de) Vernetzte, nicht von pilzen kommende lipase enthaltende zusammensetzung und methoden zu deren verwendung
DE69810091D1 (de) Verwendung von interleukin-15
MA27035A1 (fr) Ligands de recepteurs de 5-ht et leurs utilisations
DE60014348T8 (de) Messung und verwendung von molekularen wechselwirkungen
TR200102401T2 (tr) C-21 Değiştirilmiş epotilonlar.
BR0200472B1 (pt) composiÇço de fluido de hidrocarboneto lÍquido em forma de gel, e, agente de formaÇço de gel de lÍquido de hidrocarboneto.
DE60115217D1 (de) Alprazolam inklusion-komplexe und ihre pharmazeutischen zusammensetzungen
ATE412432T1 (de) Internalisierende erbb2 antikörper
FR11C0053I2 (fr) Molecules ctla4 mutantes solubles et leurs utilisations
WO2005058283A3 (en) Stabilised compositions of factor vii polypeptides
ATE343378T1 (de) Biologisch abbaubares alginatgel mit verzögerter freisetzung
TR200000740T2 (tr) Dişleri beyazlatmak için metod ve kompozisyonlar.
AU2003303458A1 (en) Ampholytic copolymer and use thereof
ATE209622T1 (de) Triaromatische verbindungen, diese enthaltende zusammensetzungen sowie ihre anwendungen
DE60005994D1 (de) Verflüssigbare pulverzusammensetzungen
DE60010761D1 (de) Initiator/amidine komplexe, solche komplexe enthaltende systeme, und damit hergestellte polymerisierte zusammensetzungen
ATE319416T1 (de) Puderzusammensetzungen
ATE426638T1 (de) Formulierung enthaltend eine anionische verbindung, ein polyionisches polymer und ein copolymer
TR200100455T2 (tr) Nimesulid içeren topikal farmasötik bileşimler
DE50206094D1 (de) Substituierte isoindole und ihre verwendung
TR199802270A2 (xx) S�lfonamid-ikame etmi� anelize 5-halka-bile�ikleri.
WO2000039154A8 (de) Peptide des at1-rezeptors und ihre verwendung bei präeklampsie und maligner hypertonie

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1407267

Country of ref document: EP